^
Association details:
Biomarker:EGFR mutation
Cancer:Non Small Cell Lung Cancer
Regimen:ABCP (Avastin (bevacizumab) + carboplatin + paclitaxel + Tecentriq (atezolizumab))
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: B - Late Trials
Title:

A Phase 3, Randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR or ALK mutated in non-small cell lung cancer (ATTLAS, KCSG-LU19-04)

Published date:
10/20/2023
Excerpt:
A total of 228 patients with activating EGFR mutation (n=215) or ALK translocation (n=13) were enrolled from 16 sites in the Republic of Korea and randomized at 2:1 ratio to either ABCP (n=154) or PC arm (n=74….Objective response rates (69.5% vs 41.9%, P <0.001) and median PFS (8.48 vs. 5.62 months, hazard ratio [HR] 0.62 [0.45-0.86], P=0.004) were significantly better in the ABCP than PC arm.
DOI:
10.1200/JCO.23.01891
Evidence Level:
Sensitive: B - Late Trials
Title:

Atezolizumab + Bevacizumab and Chemotherapy in NSCLC Subgroups With EGFR Mutations or Liver or Brain Metastases

Published date:
10/21/2021
Excerpt:
At data cutoff (September 13, 2019; median follow-up, 39.3 months), OS improvements were sustained with ABCP versus BCP in sensitizing EGFR mutations (all: hazard ratio [HR] 0.60; 95% CI: 0.31-1.14; prior tyrosine kinase inhibitor [TKI]: HR 0.74; 95% CI: 0.38-1.46) and baseline liver metastases (HR 0.68; 95% CI: 0.45-1.02) subgroups....This final exploratory analysis showed OS benefits for ABCP versus BCP in patients with sensitizing EGFR mutations...
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

NSCLC with uncommon EGFR mutations treated with atezolizumab plus bevacizumab and chemotherapy

Published date:
11/13/2022
Excerpt:
In this retrospective analysis, ABCP achieves an encouraging outcome for patients with uncommon EGFR mutations and is a valuable option in the early treatment course.
DOI:
https://doi.org/10.1016/j.lungcan.2022.11.006
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

NSCLC with uncommon EGFR mutations treated with atezolizumab plus bevacizumab and chemotherapy.

Published date:
05/26/2022
Excerpt:
Analysis included 16 stage IV NSCLC patients with uncommon EGFR mutations from 9 different German centers which started treatment in first or further line with Atezolizumab, Bevacizumab, Carboplatin and (nab-)Paclitaxel (ABCP)...In this retrospective analysis, ABCP achieves an encouraging outcome for patients with uncommon EGFR mutations, comparable to results for common EGFR mutations in IMpower150 (ORR 71%, mPFS: 9.7 months, mOS 29.4 months).
DOI:
10.1200/JCO.2022.40.16_suppl.e21076